MedTrace Logo

Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors

NCT04787003 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-23

No results posted yet for this study

Summary

Phase Ia: To investigate the safety, tolerability and efficacy of OVV-01 injection in the treatment of patients with advanced solid tumors (OVV-01 single dose gradient exploration).

Phase Ib: To evaluate the safety, tolerability and efficacy of OVV-01 injection combined with immune checkpoint inhibitors pembrolizumab (anti-PD-1 monoclonal antibody) or atezolizumab (anti-PD-L1 monoclonal antibody) in the treatment of patients with advanced solid tumors (OVV-01 combined with PD-1/PD-L1 monoclonal antibody dose gradient exploration);

Phase Ic: A cohort expansion of Phase Ib to further analyze the efficacy and safety of OVV-01 injection combined with immune checkpoint inhibitor injection in the treatment of advanced solid tumors.

Conditions

  • Neoplasms

Interventions

DRUG

oncolytic virus (OVV-01) injection

intratumoral injection of OVV-01 with or without immune checkpoint inhibitors

Sponsors & Collaborators

  • Joint Biosciences Ltd

    collaborator UNKNOWN

  • North China Petroleum Bureau General Hospital

    lead OTHER

Principal Investigators

  • Qiang Lin, Ph.D · North China Petroleum Bureau General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2023-10-01
Completion
2024-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04787003 on ClinicalTrials.gov